secwatch / observer
AKBA Akebia Therapeutics, Inc.
CIK 0001517022 50 ready 8-Ks latest August 5, 2026, 4:09 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline
Ready 8-Ks 50
Latest filing August 5, 2026, 4:09 PM ET
Top materiality 0.85
Event mix other_material ×15 · earnings ×13 · leadership ×8
Sentiment 11 pos · 6 neg · 33 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for AKBA

Highest-materiality recent filing

VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped

June 30, 2026, 8:05 AM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

Read filing →

Executive changes

Appointed

Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-06-24
Filed
June 24, 2024, 7:59 PM ET
On June 24, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Erik Ostrowski as the Company’s Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024
Appointed (interim)

John Butler

interim principal financial officer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-03-22
Filed
March 15, 2024, 7:59 PM ET
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.
Departed

Ellen Snow

Senior Vice President, Chief Financial Officer and Treasurer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-03-22
Successor
John Butler
Filed
March 15, 2024, 7:59 PM ET
On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).
Departed

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Secretary
AKBA · Akebia Therapeutics, Inc.
Effective
2024-06-14
Filed
February 13, 2024, 6:59 PM ET
On February 8, 2024, the Company and Ms. Hadas agreed to further extend the effective date of her separation to June 14, 2024
Departed

Michel Dahan

Chief Operating Officer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-06-28
Filed
February 13, 2024, 6:59 PM ET
On February 8, 2024, the Company and Mr. Dahan agreed to further extend the effective date of his separation to June 28, 2024
Appointed

Richard C. Malabre

Chief Accounting Officer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-01-08
Filed
January 8, 2024, 6:59 PM ET
On January 8, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024 (the “Effective Date”).
Departed

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Corporate Secretary
AKBA · Akebia Therapeutics, Inc.
Effective
2024-03-29
Filed
October 12, 2023, 7:59 PM ET
On October 6, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to March 29, 2024, unless the Company and Ms. Hadas agree to an earlier termination date.
Departed

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Corporate Secretary
AKBA · Akebia Therapeutics, Inc.
Effective
2023-10-06
Filed
August 1, 2023, 7:59 PM ET
On July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024
Departed

Michel Dahan

Chief Operating Officer
AKBA · Akebia Therapeutics, Inc.
Effective
2024-03-22
Filed
August 1, 2023, 7:59 PM ET
On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024
Role change (interim)

John Butler

interim principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-06-23
Filed
June 13, 2023, 7:59 PM ET
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer and principal accounting officer from the Transition Date until the Effective Date.
Appointed

Ellen Snow

Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-07-17
Filed
June 13, 2023, 7:59 PM ET
On June 12, 2023 , the Company announced that Ellen Snow will succeed Mr. Spellman as the Company’s Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective July 17, 2023 (the “Effective Date”).
Departed

David A. Spellman

Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
AKBA · Akebia Therapeutics, Inc.
Effective
2023-06-23
Successor
Ellen Snow
Filed
June 13, 2023, 7:59 PM ET
On June 9, 2023, David A. Spellman, Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign.

Earnings & guidance

2026-Q1 EPS reported -$0.03 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.62 · Most common event other_material

11 positive 6 negative 33 neutral

source · AKBA on sec.gov